AURA Insider Trading
Aura Biosciences, Inc. | Biological Products, (No Diagnostic Substances)
Comprehensive Trading Performance Summary
The investment history of corporate insiders at Aura Biosciences, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-18 03:48 | 2026-02-17 | Kilroy Conor | Officer - See Remarks | SELL | $5.05 | 12,079 | $60,999 | 167,234 | -6.7% |
| 2026-02-18 03:47 | 2026-02-17 | Plavsic Mark | Officer - Chief Technology Officer | SELL | $5.05 | 15,890 | $80,245 | 181,397 | -8.1% |
| 2026-02-18 03:47 | 2026-02-17 | Hopkins Janet Jill | Officer - Chief Medical Officer | SELL | $5.06 | 20,401 | $103,229 | 232,284 | -8.1% |
| 2026-02-18 03:47 | 2026-02-17 | Elazzouzi Amy | Officer - Senior Vice President, Finance | SELL | $5.06 | 8,549 | $43,258 | 75,532 | -10.2% |
| 2026-02-18 03:46 | 2026-02-17 | de los Pinos Elisabet | Director, Officer - See Remarks | SELL | $5.06 | 47,648 | $241,099 | 409,815 | -10.4% |
| 2026-01-21 02:41 | 2026-01-20 | Elazzouzi Amy | Officer - Senior Vice President, Finance | SELL | $4.86 | 1,581 | $7,684 | 84,081 | -1.8% |
| 2026-01-21 02:41 | 2026-01-20 | de los Pinos Elisabet | Director, Officer - See Remarks | SELL | $4.86 | 16,928 | $82,270 | 457,463 | -3.6% |
| 2025-11-18 01:56 | 2025-11-17 | Hopkins Janet Jill | Officer - Chief Medical Officer | SELL | $5.42 | 17,109 | $92,731 | 252,685 | -6.3% |
| 2025-10-30 00:05 | 2025-10-29 | Elazzouzi Amy | Officer - Senior Vice President, Finance | SELL | $6.35 | 896 | $5,690 | 85,662 | -1.0% |
| 2025-10-30 00:05 | 2025-10-29 | de los Pinos Elisabet | Director, Officer - See Remarks | SELL | $6.35 | 9,049 | $57,461 | 474,391 | -1.9% |
| 2025-10-17 00:44 | 2025-10-16 | Plavsic Mark | Officer - Chief Technology Officer | SELL | $6.35 | 12,169 | $77,273 | 197,287 | -5.8% |
| 2025-08-18 23:34 | 2025-08-18 | Elazzouzi Amy | Officer - Senior Vice President, Finance | OPT+S | $6.70 | 7,722 | $51,737 | 86,558 | 0.0% |
| 2025-05-21 00:43 | 2025-05-16 | Johnson David Michael | Director | BUY | $4.90 | 20,000 | $98,000 | 166,167 | +13.7% |
| 2025-05-21 00:34 | 2025-05-16 | Gibney Anthony S | Officer - See Remarks | BUY | $4.90 | 50,000 | $245,000 | 58,452 | +591.6% |
| 2025-05-21 00:34 | 2025-05-16 | Gibney Anthony S | Officer - See Remarks | SELL | $5.15 | 1,519 | $7,823 | 56,933 | -2.6% |
| 2025-04-17 03:36 | 2025-04-16 | Elazzouzi Amy | Officer - Senior Vice President, Finance | SELL | $5.49 | 897 | $4,925 | 81,381 | -1.1% |
| 2025-04-17 03:36 | 2025-04-16 | Kilroy Conor | Officer - See Remarks | SELL | $5.49 | 7,162 | $39,319 | 179,313 | -3.8% |
| 2025-02-19 03:31 | 2025-02-18 | Plavsic Mark | Officer - Chief Technology Officer | SELL | $7.75 | 2,151 | $16,670 | 209,456 | -1.0% |
| 2025-02-19 03:31 | 2025-02-18 | Elazzouzi Amy | Officer - Senior Vice President, Finance | SELL | $7.75 | 1,404 | $10,881 | 82,278 | -1.7% |
| 2025-02-19 03:30 | 2025-02-18 | Hopkins Janet Jill | Officer - Chief Medical Officer | SELL | $7.75 | 2,534 | $19,639 | 269,794 | -0.9% |
| 2025-02-19 03:30 | 2025-02-18 | de los Pinos Elisabet | Director, Officer - See Remarks | SELL | $7.75 | 20,221 | $156,796 | 482,440 | -4.0% |
| 2025-01-22 05:09 | 2025-01-21 | de los Pinos Elisabet | Director, Officer - See Remarks | SELL | $7.67 | 15,955 | $122,381 | 304,692 | -5.0% |
| 2025-01-22 05:09 | 2025-01-21 | Elazzouzi Amy | Officer - Vice President, Finance | SELL | $7.67 | 1,001 | $7,679 | 38,442 | -2.5% |
| 2024-11-19 05:06 | 2024-11-18 | Hopkins Janet Jill | Officer - Chief Medical Officer | SELL | $9.36 | 11,822 | $110,663 | 151,693 | -7.2% |
| 2024-10-30 03:28 | 2024-10-29 | de los Pinos Elisabet | Director, Officer - See Remarks | SELL | $10.74 | 9,200 | $98,788 | 320,647 | -2.8% |
| 2024-10-30 03:23 | 2024-10-29 | Elazzouzi Amy | Officer - Vice President, Finance | SELL | $10.74 | 553 | $5,938 | 39,443 | -1.4% |
| 2024-10-22 01:23 | 2024-10-18 | Feder Julie B | Officer - Chief Financial Officer | OPT+S | $12.03 | 25,131 | $302,361 | 134,276 | 0.0% |
| 2024-10-19 03:08 | 2024-10-18 | de los Pinos Elisabet | Director, Officer - See Remarks | OPT+S | $12.04 | 24,992 | $300,839 | 329,847 | 0.0% |
| 2024-10-17 04:25 | 2024-10-16 | Plavsic Mark | Officer - Chief Technology Officer | SELL | $9.85 | 7,383 | $72,723 | 121,132 | -5.7% |
| 2024-01-25 00:20 | 2024-01-23 | de los Pinos Elisabet | Director, Officer - See Remarks | SELL | $7.64 | 15,853 | $121,141 | 161,438 | -8.9% |
| 2024-01-25 00:18 | 2024-01-23 | Feder Julie B | Officer - Chief Financial Officer | SELL | $7.64 | 6,609 | $50,521 | 62,991 | -9.5% |
| 2023-11-10 01:02 | 2023-11-07 | Johnson David Michael | Director | BUY | $7.19 | 199,601 | $1,434,991 | 75,000 | +100.0% |
| 2023-11-10 00:35 | 2023-11-09 | Matrix Capital Management Company, LP | 10% owner | BUY | $9.00 | 1,560,000 | $14,040,000 | 6,922,870 | +29.1% |
| 2023-11-08 02:19 | 2023-11-06 | de los Pinos Elisabet | Director, Officer - See Remarks | OPT+S | $12.03 | 7,449 | $89,611 | 177,291 | 0.0% |
| 2023-11-08 02:09 | 2023-11-06 | Feder Julie B | Officer - Chief Financial Officer | OPT+S | $12.07 | 3,900 | $47,054 | 69,600 | 0.0% |
| 2023-11-02 01:24 | 2023-10-30 | Feder Julie B | Officer - Chief Financial Officer | SELL | $6.82 | 3,385 | $23,091 | 69,600 | -4.6% |
| 2023-11-02 01:21 | 2023-10-30 | de los Pinos Elisabet | Director, Officer - See Remarks | SELL | $6.83 | 9,586 | $65,478 | 180,940 | -5.0% |
| 2023-10-06 02:56 | 2023-10-03 | Johnson David Michael | Director | BUY | $8.38 | 20,066 | $168,175 | 50,066 | +66.9% |
| 2023-01-10 01:55 | 2023-01-05 | Johnson David Michael | Director | BUY | $10.41 | 2,000 | $20,811 | 18,000 | +12.5% |
| 2022-12-31 03:01 | 2022-12-28 | Johnson David Michael | Director | BUY | $9.75 | 4,000 | $39,000 | 17,000 | +30.8% |
| 2022-12-16 02:15 | 2022-12-01 | Johnson David Michael | Director | BUY | $12.37 | 10,000 | $123,700 | 15,000 | +200.0% |
| 2022-12-08 00:30 | 2022-12-05 | Matrix Capital Management Company, LP | 10% owner | BUY | $12.00 | 1,250,000 | $15,000,000 | 5,362,870 | +30.4% |
| 2022-11-03 03:39 | 2022-10-31 | Feder Julie B | Officer - Chief Financial Officer | SELL | $12.45 | 2,015 | $25,090 | 24,235 | -7.7% |
| 2022-11-03 03:38 | 2022-10-31 | Rich Cadmus | Officer - See Remarks | SELL | $12.45 | 1,672 | $20,813 | 24,578 | -6.4% |
| 2022-11-03 03:37 | 2022-10-31 | de los Pinos Elisabet | Director, Officer - See Remarks | SELL | $12.46 | 5,706 | $71,082 | 68,651 | -7.7% |
| 2022-11-03 03:36 | 2022-10-31 | De Rosch Mark | Officer - Chief Operating Officer | SELL | $12.46 | 1,115 | $13,890 | 16,385 | -6.4% |
| 2022-06-15 04:29 | 2022-06-10 | Johnson David Michael | Director | BUY | $14.33 | 50,000 | $716,300 | 30,000 | +100.0% |
| 2021-11-05 00:00 | 2021-11-02 | Medicxi Ventures Management (Jersey) Ltd | 10% owner | BUY | $14.00 | 710,000 | $9,940,000 | 70,540 | +100.0% |
| 2021-11-04 23:44 | 2021-11-02 | Matrix Capital Management Company, LP | 10% owner | BUY | $14.00 | 1,785,000 | $24,990,000 | 4,112,870 | +76.7% |
How to Interpret $AURA Trades
Not every insider transaction in Aura Biosciences, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $AURA shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for AURA
Insider activity data for Aura Biosciences, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $AURA, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.